Kardium

Kardium, founded in 2007, is a prominent medical technology company specializing in the development of advanced cardiac ablation solutions. The firm is recognized for its Globe Pulsed Field System, an integrated platform that combines high-density cardiac mapping with precise pulsed-field ablation. This all-in-one catheter technology is designed to streamline clinical workflows, allowing physicians to visualize cardiac activity while tailoring therapy to individual patient needs. By focusing on procedural control and efficiency, Kardium addresses critical challenges in the treatment of atrial fibrillation.

Operating from its headquarters in Burnaby, Canada, Kardium maintains a robust workforce of 500-1,000 employees dedicated to medical device innovation and manufacturing. The company’s organizational structure supports complex R&D and global market expansion, ensuring high standards in medical equipment production. Meet Kardium's team to learn more about the leadership and technical experts driving these advancements in cardiac care. The company continues to leverage its expertise to refine its ablation systems, maintaining a competitive edge in the medical device sector.

Kardium has demonstrated significant financial growth, reporting annual revenue of $175.5M. The company’s funding history includes substantial backing from major institutional investors, including Fidelity Management & Research Company and T. Rowe Price, alongside support from the Government of Canada. This capital infusion supports ongoing research and development efforts aimed at enhancing patient outcomes in arrhythmia treatment. Explore financial highlights for detailed metrics regarding the company's fiscal performance and investment trajectory. Kardium remains a key player in the medical device market, competing with firms like Axonics and Quanta Dialysis Technologies.